title: Primary trabeculectomy with mitomycin C: safety and efficacy at 2 years.
abstract: OBJECTIVE
  To examine the rates of intermediate-term intraocular pressure (IOP) control after trabeculectomy with adjunctive mitomycin C (MMC) and assess for associated complications.
  
  
  METHODS
  Medical records of patients undergoing primary trabeculectomy with MMC at Concord Repatriation Hospital, Sydney between January 1997 and December 2005 were reviewed. All eyes with a minimum of 2-year follow up were included. Follow-up data were collected in a standardized form on postoperative IOP, bleb-related and other complications. Success was measured as IOP ≤ 18 mmHg and ≥ 6 mmHg (criteria 1) with (qualified success) or without (absolute success) the use of glaucoma medications. A secondary outcome measure was an IOP reduction of greater than 20% from baseline (criteria 2). Eyes with preoperative IOP of 18 mmHg or less were included, but also analysed separately to those eyes with preoperative IOP above 18 mmHg.
  
  
  RESULTS
  Sixty eyes from 42 patients were included in the study, with 3-year follow up on 48 eyes. Mean preoperative IOP was 25.3 mmHg (range 8-45) and mean postoperative IOP was 14.0 mmHg at 1- and 2-year follow up, and 14.7 mmHg at 3 years (ranges: 3-31, 4-30 and 8-45 mmHg respectively). Cumulative success for criteria 1 was 85.0% at 2 years and 83.3% at 3 years, and for criteria 2 it was 80.0% and 79.2%, respectively. The number of eyes on glaucoma medications was reduced from 51 preoperatively to 30 at 3 years. Complications were infrequent. There was one eye with a shallow anterior chamber beyond the immediate postoperative period. One eye required cataract surgery at 1-year follow up. Subgroup analysis was performed using the first operated eye only, and results did not differ significantly from overall results.
  
  
  CONCLUSIONS
  MMC-augmented trabeculectomy can significantly reduce IOP in the short and intermediate term, with a favourable safety profile.
authors.affiliation: Concord Repatriation General Hospital, Sydney, New South Wales, Australia. jed.lusthaus@gmail.com
authors.forename: Jed A
authors.initials: JA
authors.lastname: Lusthaus
authors.forename: Olena
authors.initials: O
authors.lastname: Kubay
authors.forename: Rushmia
authors.initials: R
authors.lastname: Karim
authors.forename: David
authors.initials: D
authors.lastname: Wechsler
authors.forename: Frances
authors.initials: F
authors.lastname: Booth
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects*; D019384:Nucleic Acid Synthesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D015814:Ocular Hypotension / Q000517:prevention & control; D011183:Postoperative Complications / Q000188:drug therapy / Q000517:prevention & control*; D012189:Retrospective Studies; D014130:Trabeculectomy / Q000009:adverse effects* / Q000379:methods*; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D019384:Nucleic Acid Synthesis Inhibitors; D016685:Mitomycin